Neukio Biotherapeutics Funding: $90M Raised, Series A (2022)
Neukio Biotherapeutics is based in Shanghai, China. It has raised $90M in total funding. Latest round: Series A.
Neukio Biotherapeutics funding overview
Neukio Biotherapeutics is based in Shanghai, China. Neukio Biotherapeutics has raised $90M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in September 2022. The round record for Neukio Biotherapeutics runs through 2022; nothing later has been disclosed. Investors on record include CD Capital, Alwin Capital, Surplus Capital, Lilly Asia Ventures, Sherpa Healthcare Partners, IDG Capital. 6 distinct backers are named across the disclosed rounds.
Neukio Biotherapeutics at a glance
Total raised
$90M
Latest round
Series A
Latest round date
September 2022
Headquarters
Shanghai, China
Notable investors
CD Capital, Alwin Capital, Surplus Capital, Lilly Asia Ventures, Sherpa Healthcare Partners, IDG Capital
Frequently asked about Neukio Biotherapeutics funding
How much has Neukio Biotherapeutics raised?
Neukio Biotherapeutics has raised $90M in total disclosed funding across the rounds on record.
Who has invested in Neukio Biotherapeutics?
CD Capital, Alwin Capital, Surplus Capital, Lilly Asia Ventures, Sherpa Healthcare Partners, IDG Capital are named among the investors backing Neukio Biotherapeutics.
What was the latest Neukio Biotherapeutics funding round?
The most recent disclosed round is a Series A, announced in September 2022.
Where is Neukio Biotherapeutics based?
Neukio Biotherapeutics is based in Shanghai, China.
When did Neukio Biotherapeutics last raise?
The last disclosed Neukio Biotherapeutics round closed in September 2022 at Series A.
Every Neukio Biotherapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Shanghai at a similar stage.
